Cytori Therapeutics Inc (NASDAQ:CYTX) Closed Much Higher Than Its 50 Day Average


Shares last traded at $0.52 a great deal higher than the 50 day moving average of $0.42 and which is well below the 200 day moving average of $0.75. The 50 day moving average went up $0.11 or +25.6971% whereas the 200 day average was down by -29.9416%. Trading volume for Cytori Therapeutics Inc was 149K on Tuesday. Shares saw a steep decrease in trading volume of 68.51% under the normal average daily volume.

Short traders are more bullish lately looking at the motion in short interest. The firm had a fall in short interest of -9.79% as of the latest report on September 29, 2017. Short interest decreased 168,362 over that period. The days to cover decreased to 3.0 and the percentage of shorted shares is 0.05% as of September 29.

Additionally, here are a few investment firms who have increased or decreased their stake in (CYTX). As of quarter end Citadel Advisors LLC had bought a total of 34,242 shares growing its holdings by 282.8%. The value of the investment in (CYTX) increased from $2,000 to $10,000 a change of 400.0% quarter to quarter. As of the end of the quarter UMB Bank N A/mo had disposed of 6,251 shares trimming its stake by 50.5%. The value of the company’s investment in Cytori Therapeutics Inc went from $14,000 to $2,000 decreasing 85.7% for the reporting period.

As of the latest earnings report the EPS was $-1.00 and is estimated to be $-0.60 for the current year with 34,716,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $-0.10 with next year’s EPS projected to be $-0.43.

Cytori Therapeutics, Inc., a biotechnology company, develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets to commercial customers, as well as for research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. In addition, the company provides StemSource devices, including a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system, as well as offers consulting, installation, and training services. Cytori Therapeutics, Inc. markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales reps, distributors, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California..